

## Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

**Ghent, BELGIUM – 12 November 2020 – Sequana Medical NV (Euronext Brussels: SEQUA)**, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020.

### Company presentation with live webcast

- Thursday, 19 November 2020 at 11:35 am CET
- To register for the webcast, click [here](#)
- The presentation and a replay of the webcast will be available on [Sequana Medical's Investors website](#) shortly after the event

To request a one-on-one meeting with the Sequana Medical management team, contact us at [IR@sequanamedical.com](mailto:IR@sequanamedical.com).

### For more information, please contact:

#### Sequana Medical

Lies Vanneste, Director Investor Relations

Tel: +32 (0) 498 05 35 79

Email: [IR@sequanamedical.com](mailto:IR@sequanamedical.com)

#### Consilium Strategic Communications

Amber Fennell, Ashley Tapp, Melissa Gardiner

Tel: +44 203 709 5000

Email: [sequanamedical@consilium-comms.com](mailto:sequanamedical@consilium-comms.com)

#### LifeSci Advisors

Chris Maggos

Tel: +41 79 367 6254

Email: [chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

### About Sequana Medical

Sequana Medical is a commercial stage medical device company developing the **alfapump** platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a fast growing complication of advanced liver disease driven by NASH (non-alcoholic steatohepatitis) related cirrhosis and a common complication in heart failure. The U.S. market for the **alfapump** resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for the **alfapump** DSR (Direct Sodium Removal) is estimated to be over €5 billion annually in the U.S. and EU5 by 2026. Both indications leverage Sequana Medical's **alfapump**, a unique, fully implanted wireless device that automatically pumps fluid from the abdomen into the bladder, where it is naturally eliminated through urination.

In the U.S., the company's key growth market, the **alfapump** has been granted breakthrough device designation by the FDA. The North American pivotal study (POSEIDON) in recurrent and refractory ascites due to liver cirrhosis is currently underway, and is intended to support a commercial marketing application of the **alfapump** in the U.S. and Canada. In Europe, the **alfapump** is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 800 **alfapump** systems have been implanted to date. Building on its proven **alfapump** platform, Sequana Medical is developing the **alfapump** DSR, a breakthrough, proprietary approach to fluid overload due to heart failure. Clinical proof-

of-concept was achieved in a first-in-human single dose DSR study and further supported by strong interim safety and efficacy results from the ongoing repeated dose **alfapump** DSR study (RED DESERT) in heart failure patients.

Sequana Medical is headquartered in Ghent, Belgium. For further information, please visit [www.sequanamedical.com](http://www.sequanamedical.com).

**Important Regulatory Disclaimers**

*The **alfapump**® system is not currently approved in the United States or Canada. In the United States and Canada, the **alfapump**® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see [www.poseidonstudy.com](http://www.poseidonstudy.com). The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the **alfapump**® system in Europe.*

**Forward-looking statements**

*This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.*